SLNO
Closed
Soleno Therapeutics Inc
82.69
-1.09 (-1.30%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 83.78
Day's Range: 81.61 - 84.68
Send
sign up or login to leave a comment!
When Written:
2.45
Soleno Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on the development of novel therapeutics for rare diseases. The company's lead product candidate is DCCR (diazoxide choline controlled-release), which is being developed for the treatment of Prader-Willi Syndrome (PWS), a rare genetic disorder that causes hyperphagia (excessive eating) and obesity.
Soleno Therapeutics was founded in 1999 and is headquartered in Redwood City, California. The company's mission is to develop innovative therapies that can improve the lives of patients with rare diseases.
In addition to DCCR, Soleno Therapeutics is also developing other product candidates for rare diseases, including a treatment for amyotrophic lateral sclerosis (ALS) and a treatment for sickle cell disease.
The company is publicly traded on the NASDAQ stock exchange under the ticker symbol "SLNO".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Soleno Therapeutics was founded in 1999 and is headquartered in Redwood City, California. The company's mission is to develop innovative therapies that can improve the lives of patients with rare diseases.
In addition to DCCR, Soleno Therapeutics is also developing other product candidates for rare diseases, including a treatment for amyotrophic lateral sclerosis (ALS) and a treatment for sickle cell disease.
The company is publicly traded on the NASDAQ stock exchange under the ticker symbol "SLNO".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!